In this work, we use a set of fifteen ODEs to model not only the virus but also immune cells, antibodies and cytokines. Du and Yuan (2020) developed a mathematical model to investigate the dynamics of ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Cytokine Release Syndrome (CRS) is a major concern in CAR-T therapy. How do you approach the grading and management of CRS? Which strategies have you found most effective for reducing the severity of ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

may cause a complication that resembles secondary HLH and is distinct from — and typically occurs later after CAR T-cell infusion than — cytokine release syndrome. This HLH-like complication ...

We investigated presence and severity of cytokine release syndrome and ICANS using logistic regression and progression-free survival and overall survival using Cox regression. Multivariable models ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...